Diagnose Earlier.
Treat Sooner.
Measure Outcomes.
FDA-cleared eye-tracking technology using visual attention biomarkers for autism to support early diagnosis and measurable treatment outcomes—starting as young as 16 months.
How It Works
Supporting Timely, Informed Care
Same-day results help guide discussions with families and care teams.
The EarliPoint System device is indicated for use as a tool to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children ages 16 months through 30 months who are at risk based on concerns identified by a parent, caregiver, or healthcare provider (Not for direct consumer purchase; clinician use only).
Railey & Associates uses Creyos to deliver objective, scientifically validated assessments.
These tools support early detection and diagnostic clarity for ADHD, dementia, and other mental health conditions.
EarliPoint® Clinical Validation Trials
EarliPoint’s recent studies, featured in The Journal of the American Medical Association (JAMA), reveal the effectiveness of quantifying moment-by-moment looking behavior as a biomarker for objectively assessing the presence or absence of autism. These studies also measure individual children’s functioning across the three core domains of autism – social disability, verbal ability, and nonverbal learning.
